Introduction: From Population-Based Medicine to Individualized Care

Two patients can walk into the same clinic with the same diagnosis and leave with two entirely different biological stories. Same labs, same presenting symptoms, same diagnostic code, and yet one responds well to a first-line treatment while the other doesn’t respond at all, or worse, has an adverse reaction. This is a familiar experience for any healthcare provider treating complex or chronic conditions and patients just looking to optimize their health.

Modern medicine has made enormous progress by defining disease and establishing standards of care. But patients with the same diagnosis, similar labs, or similar symptoms can still respond very differently to treatment. Those differences may reflect important biological individuality that standardized approaches do not always fully capture.

Genomics provides access to that biological individuality by revealing inherited variation, predispositions, pathways, and mechanisms that may not otherwise be visible in routine clinical care. Rather than treating every patient with a given diagnosis identically, genomic information can help healthcare providers begin to individualize care based on how a specific patient’s body actually processes, responds to, and regulates the systems involved.

Key Takeaways

• Patients with the same diagnosis can have very different underlying biology, which can help explain why standardized approaches don’t work equally well for everyone.
• Genomics adds biological context that can help clinicians understand what may be contributing to a patient’s presentation, supporting more individualized prevention, monitoring, and treatment decisions.
• Pharmacogenomics can inform medication selection by highlighting individual differences in drug metabolism, transport, targets, and adverse-event risk.
• Raw genomic data alone isn’t clinically actionable; it requires interpretation through variant classification, evidence quality, and pathway-level context to be useful in practice.
• Precision medicine works best when genomic information informs clinical judgment rather than replacing it, helping clinicians move from a diagnosis alone toward a clearer picture of the individual patient.

Personalized Medicine vs. Precision Medicine

The terms “personalized medicine” and “precision medicine” are often used interchangeably, but they describe slightly different ideas.

Personalized medicine refers to the broader philosophy of tailoring care to the individual patient, their history, preferences, environment, and biology, rather than applying a one-size-fits-all protocol.

Precision medicine is a more specific, data-driven approach that uses molecular and genomic information, along with lifestyle and environmental factors, to guide prevention, diagnostics, and treatment decisions for a particular patient or patient subgroup.

In practice, genomic medicine is one of the primary contributors that makes precision medicine possible, and it’s a key factor of truly personalized care.

What Is Genomics, and Why Does It Matter in Clinical Medicine?

The human genome contains the complete set of genetic instructions that influence how the body functions. Genetic variation, differences in that code from person to person, can influence far more than eye color or ancestry. It can shape:

• Drug metabolism and response: how quickly or slowly a patient breaks down a medication
• Disease susceptibility: which conditions a patient may be more or less predisposed to
• Immune and inflammatory signaling: how a patient’s immune system responds to triggers
• Nutrient metabolism: how efficiently a patient processes and utilizes key nutrients
• Hormonal pathways: how hormones are produced, converted, and cleared
• Cellular processes and biological resilience: how well a patient’s cells manage stress, detoxification, and repair

It’s worth distinguishing a few related terms that are often used loosely:

• Genetics typically refers to the study of single genes and inherited conditions, for example, rare diseases caused by a variant in one specific gene.
• Genomics is the broader study of the entire genome and how many genes interact with each other and with the environment, relevant to complex, chronic conditions that don’t trace back to a single gene.
• Pharmacogenomics is the study of how genomic variation affects an individual’s response to specific medications, informing dosing, drug selection, and adverse-event risk.
• Genomic biomarkers are measurable genomic indicators that may be associated with disease risk, drug response, or other clinically relevant patterns.

Biomarkers can help show what is happening in a patient at a given point in time. Genomics can help illuminate why it may be happening, adding information about the underlying pathways and predispositions that a biomarker alone doesn’t explain.

Clinician takeaway: Genomic information is most useful when it adds actionable biological context to the patient’s existing clinical picture.

How Genomics Supports Personalized Medicine

Identifying Individual Differences in Disease Risk

Genomic information can help clinicians understand a patient’s disease risk profile, but it’s important to be precise about what that means. Genetic predisposition refers to an increased likelihood of developing a condition based on genomic variants; it is not the same as genetic determinism, the idea that a gene variant guarantees an outcome. Most common chronic conditions are influenced by many interacting variants, plus environmental and lifestyle factors, meaning risk is rarely fixed. This is where modifiable risk becomes clinically meaningful: understanding which risk factors can potentially be influenced through prevention, monitoring, or lifestyle change.

Understanding Biological Pathways Behind Clinical Presentations

Clinically meaningful genomic insight often comes from considering multiple variants together and understanding how they may interact across biological pathways relevant to disease, prevention, and health optimization.

Genomic interpretation is moving beyond a single-variant, single-gene approach. In most complex conditions, multiple variants may converge on interconnected biological pathways rather than acting in isolation. Some of the pathways clinicians most commonly evaluate include:

• Inflammation and immune regulation
• Oxidative stress
• Methylation
• Detoxification
• Lipid metabolism
• Neurotransmitter pathways

Looking at a patient’s biology through the lens of interacting pathways, rather than isolated genes, can help clinicians begin to understand what may be contributing to a presentation that hasn’t responded to standard approaches. Two findings that looked unrelated on their own may turn out to sit on the same pathway, and that relationship can raise a question worth exploring further.

Individualizing Prevention and Monitoring

Genomic insights may also help clinicians identify areas where earlier prevention or closer monitoring could be appropriate for a specific patient, supporting more informed clinical decisions about screening frequency, risk-factor management, or areas warranting further evaluation, in the context of the patient’s full clinical history.

How Genomics Enables Precision Treatment

Pharmacogenomics and Medication Selection

Pharmacogenomics is one of the clearest, most immediately applicable areas of genomic medicine. Genetic variation can affect:

• Metabolism: how quickly a medication is broken down
• Drug transport: how a medication moves through the body
• Drug targets: how receptors and target proteins respond to a given therapy
• Therapeutic response: whether a standard dose is likely to be effective
• Adverse-event risk: the likelihood of a poor reaction to a specific medication

For healthcare providers managing patients on multiple medications, or patients who have failed several prior treatments, pharmacogenomic information can provide meaningful context before the next prescribing decision.

Moving From “What Disease Does This Patient Have?” to “What May Be Driving It?”

Much of medicine is organized around diagnosis and established standards of care. That model works well in many situations, but it does not always capture the full biological context of the individual. In chronic and multifactorial conditions, prevention, and health optimization, genomic information can add insight into pathways, predispositions, and modifiable factors that may shape how the clinical picture is understood and how care is individualized.

Genomic information adds a second question alongside the first. Diagnosis identifies the disease category. Genomic context can help clinicians understand what may be contributing to the individual’s presentation, risk profile, or health goals.

Matching Treatment to Biology

Precision treatment means treatment decisions can incorporate a patient’s molecular characteristics alongside their phenotype and clinical history, not instead of them. Cardiology offers a useful example: two patients with similar cardiac risk factors on paper may have very different underlying contributors, lipid metabolism, inflammatory signaling, clotting factors, or other pathway-level differences, that can inform a more individualized approach to prevention and monitoring.

From Genomic Test to Clinical Insight

Testing Is Only the First Step

Ordering a genomic test, whether targeted panel testing or broader next-generation sequencing (NGS), is only the beginning. For genomic information to be clinically useful, it needs to be presented in a format clinicians can actually apply, not simply delivered as a long list of variants with no clinical framing.

Why Raw Genetic Data Is Not Enough

Raw genomic data on its own presents real challenges for clinical use, including:

• Variant classification: determining which variants are clinically meaningful
• Evidence quality: assessing how well-supported a given variant-condition association is
• Clinical relevance: connecting a variant to the patient’s actual presentation
• Gene-gene interactions: understanding how variants interact rather than act alone
• Pathway relationships: seeing how findings fit into broader biological systems
• Phenotype-genotype correlation: confirming that a genomic finding aligns with what’s actually happening clinically

Without this layer of interpretation, even accurate sequencing data can be difficult, or risky, to act on.

The Role of Genomic Intelligence and Clinical Interpretation

Appropriate application of any genomic finding depends on the specific result, the strength of its evidence base, the individual patient’s context, and the clinical question being asked. This is where genomic interpretation earns its value, helping identify which biological contributors may deserve attention first and, while leaving clinical decision-making firmly in the clinician’s hands.

How Clinicians Can Integrate Genomics Into Practice

1. Start with a clinical question. Begin with the specific presentation or concern you’re trying to understand, not genomics for its own sake.
2. Select appropriate genomic testing. Choose a testing approach, targeted panel, pharmacogenomic panel, or broader sequencing, that fits the clinical question.
3. Evaluate the evidence. Consider the strength and quality of evidence behind each genomic finding before applying it clinically.
4. Interpret findings in context. Weigh genomic results alongside labs, history, symptoms, and other clinical data, never in isolation.
5. Prioritize and translate findings into a clinical plan. Use genomic context to help identify what may deserve attention first and inform, not dictate, next steps in care.
6. Revisit the evidence over time. Genomic science evolves; findings and their clinical relevance should be reassessed as new evidence emerges.

Where Genomic Interpretation Fits Into Practice

For most healthcare providers, the challenge isn’t a lack of data. It’s translating that data into something clinically usable within an already demanding practice. IntellxxDNA was built to make genomic medicine clinically usable, helping clinicians identify biologically relevant drivers, understand the mechanisms behind them, and translate that thinking into a plan built around the patient. It does not replace clinical judgment. It strengthens it.

Conclusion

Much of medicine today is organized around diagnosis and established standards of care. That model has transformed care, but it does not always capture the full biological context of the individual. The next evolution is to bring more of that individual biology into how clinicians understand disease, prevention, risk, and health optimization. Genomic context can help reveal pathways, predispositions, and modifiable factors that may shape the clinical picture, giving clinicians a clearer biological basis for more individualized care.

Genomic insights should be interpreted within the context of comprehensive clinical evaluation and individualized care.

Ready to see how genomic insight can support your clinical decision-making? Start here to learn how IntellxxDNA helps clinicians bring genomic context into everyday patient care.

Genomic insights should be interpreted within the context of comprehensive clinical evaluation and individualized care.

What Your DNA Can Reveal About Your Immune Health

How Three Genomic Variants helped reverse Graves’ Disease

Key Takeaways

• Autoimmune disease is influenced by genetics and is rarely random. In otherwise healthy patients, it typically reflects specific genetic vulnerabilities. Genome-wide association studies (GWAS), demonstrate that many forms of autoimmunity arise from the interaction of common gene variants, rare variants, environmental factors, and immune regulation.
• The standard protocol addresses the disease. Genomics helps you understand the patient. Without addressing underlying contributors, the immune dysregulation that produced one autoimmune condition can lead to other complex diseases.
• Immune signalling pathways matter. Variants affecting genes involved in innate immunity, inflammatory signalling, gene expression, and mast cell activation may contribute to conditions including Graves’ disease, rheumatoid arthritis, systemic lupus erythematosus (SLE), systemic sclerosis, and other autoimmune disorders.
• Pattern recognition receptors matter. TLR3 variants affect how a patient’s immune system responds to triggers. They rarely surface in standard workups — but they can be central to the clinical picture.
• Three variants. One changed trajectory. This case didn’t require becoming an expert in genomics. It required a structured genomics report and a clinician willing to ask why.
• New onset autoimmune disease is rising. A 43%–49% increase in presentations including multiple autoimmune conditions such as hair loss, vitiligo, RA, and psoriasis makes understanding individual immune biology more clinically relevant than ever.

A Patient Without the Typical Risk Profile

He was doing everything right.

Marcus, a 54-year-old active and health-conscious man, presented with newly diagnosed Graves’ disease.

Aside from his diagnosis, little about his clinical history suggested he was at elevated risk of developing an autoimmune condition. He maintained a healthy lifestyle, exercised regularly, and had no obvious environmental or lifestyle factors that explained the sudden onset of disease.

His clinician treated the disease. But something kept pulling them back to the same question:

Why this patient and why now?

He wasn’t the demographic, did not fit the profile but his immune system had revolted anyway.

The doctor wasn’t ready to hand him a lifelong treatment protocol without at least trying to understand why.

So they ordered an IntellxxDNA genomic report.

What The Genomics Report Revealed

For weeks, the picture hadn’t made sense.

A healthy man with an immune system in revolt and no obvious explanation.

Then the genomics report came back.

Not a mystery anymore. A pattern, specific, coherent, and for the first time, it was visible.

All thanks to two decades of genome-wide association studies, genetic studies, and genome-wide association research. These have fundamentally changed our understanding of autoimmune disease.

Marcus’s report identified several high-impact variants affecting immune regulation.

These three variants, organized together, told a story about why Marcus’s immune system was primed to overreact, and what had likely been amplifying that response without anyone realizing it.

The first was TNF-alpha, a key driver of systemic inflammation. Marcus carried 2 variants in this pathway, only found in .8% of the population, that affects how strongly and how persistently the immune system mounts an inflammatory response. In patients with this variant, immune activation doesn’t just spike. It compounds.

Standard labs wouldn’t show it.

The second was TLR3 (Toll-Like Receptor 3), part of the innate immune system’s pattern recognition machinery. Its job is to detect threats: viral, environmental, or biological. Marcus’s 2 variants, which are only found in 3.8% of the population variant. This made the system hypersensitive and perpetually on alert and far more likely to misfire.

The third was TSLP, a signalling molecule associated with epithelial immunity, mast cell activation, and inflammatory signalling.It also works as an alarm into the immune system and is heavily involved in triggering autoimmune disease.

His body wasn’t broken.

And this was not random.

In fact, his immune system was doing precisely what his genetics had primed it to do, and no standard workup was ever going to show that.

Personalizing Clinical Management

The genomic report did not replace conventional medical management.

These weren’t exceedingly rare mutations and wouldn’t have been flagged in any way on whole genomic sequencing reports.

They weren’t exotic findings requiring specialist interpretation. They were genomic variants, the kind that sit quietly in a patient’s biology, invisible until detected, until something organizes them into a picture that finally makes clinical sense.

But they showed up on the patient’s IntellxxDNA report, because IntellxxDNA is specifically designed to help identify genomic underpinnings of chronic diseases including autoimmune disease.

That’s why the report was so valuable.

It didn’t just identify variants. It showed how they fit together.

The report was also actionable which is what made it useful. It paired each finding with evidence-based intervention considerations, including targeted supplements, dietary strategies, and lifestyle approaches, with dosing references and all grounded in published medical literature.

Three Months Later

Marcus wasn’t prescribed radioactive iodine.

He was not scheduled for surgery.

He was not prescribed a long-term thyroid-suppressing pharmacological protocol.

His doctor addressed the genomic pathways the report had made visible.

Three months later, Marcus’s antibodies had normalized.

The progression that might have led to permanent thyroid damage or a lifetime of replacement therapy did not follow the expected course. Because the care wasn’t algorithmic, it was specific to him.

Marcus still checks in. He is still active. His health, by every measure, remains stable.

Why This Matters

Marcus isn’t alone.

Autoimmune disease affects millions of people worldwide and continues to increase in prevalence.

New onset autoimmune disease has risen 43–49%

Conditions such as Graves’ disease, Hashimoto’s, rheumatoid arthritis, systemic lupus erythematosus (SLE), systemic sclerosis, type 1 diabetes, psoriasis, vitiligo, and alopecia share overlapping immune mechanisms despite presenting as distinct clinical diagnoses.

Increasing evidence suggests that many of these conditions represent related manifestations of underlying immune dysregulation rather than entirely separate disorders.

In some patients, this contributes to the development of multiple autoimmune diseases over time.
The patients arriving in your practice are increasingly like Marcus.

They’re not frail, not immunocompromised, and not following the expected demographic script. Just people whose immune systems have activated against them in ways that standard evaluations or that a diagnosis might describe but cannot fully explain.

The gap between description and explanation is where genomics does its most important work.

The structured context of a well-designed genomic report, the innate immune variants, the mast cell related alarmin. the inflammatory signaling contributions, all of it remains invisible.

And the care defaults to protocol.

If you’ve had a patient like Marcus, someone who did everything right and still ended up here, and you’ve sensed that treating the disease wasn’t the same as understanding it, you already know what was missing.

His clinician found it, but didn’t have to go digging as IntellxxDNA’s report called out all these variants so they were right in front of her. And they walked away from this case seeing every patient like him differently.

If Marcus’s case looks familiar, if you see patients with autoimmune disease, and you are not yet using IntellxxDNA’s genomics for guidance, now is the time to start.

Explore how structured genomics moves challenging cases forward with confidence.

Genomic insights should be interpreted within the context of comprehensive clinical evaluation and individualized care.

Helping One Patient Defy Her Family’s Cognitive Trajectory

Key Takeaways

• APOE4 is important, but it is rarely the whole story. Identifying a single high-risk variant without examining the full genomic picture leaves the most addressable contributors invisible and unaddressed.
• Seemingly unrelated symptoms often share a genomic root. Insomnia and gut issues that appear separate from cognitive decline can be driven by the same underlying variants — and resolving them can directly support brain health.
• Genomic insight turns risk into a roadmap. Rather than leaving a patient with a frightening statistic and no direction, structured genomic reporting identifies the specific pathways that need support and what to do about each one.
• The investment in genomic clarity pays for itself. The cost of a report is a fraction of the cost of memory care, and the difference in outcome, as Marnie’s case shows, can be measured in years of independent, healthy life.
• Sustained cognitive improvement is possible when root causes are addressed. Seven years later, Marnie’s memory score is in the normal range. She is 80 years old, living independently, and the only one of her five siblings with intact cognition.

A Turning Point Towards Biology

The symptoms are real.
The family history is real.
And the fear that comes with a diagnosis, or even a near-diagnosis, is also very real.

But a single genetic marker, however significant, is rarely the complete picture.
And treating it as such leaves too much on the table.

This is where turning toward genomics makes all the difference.

What the IntellxxDNA Genomic Report Revealed

At first glance, the picture seemed straightforward. Marnie a 72 year old woman with a strong family history of cognitive decline, carried APOE4, the most well-known genetic risk factor for Alzheimer’s disease. It’s a variant that carries approximately 3.7 times the baseline risk of dementia, compared to those without an APOE4. Baseline cognition testing was done and the patient had a memory test score of 24 on a screener where normal is 27-30. A diagnosis of mild cognitive impairment felt due to ApoE4 and other Alzheimer’s risk factors, on the surface, seemed like the obvious conclusion.

But APOE4 alone was not enough of an answer.

Her clinician used IntellxxDNA to look deeper, and what emerged was a genomic picture far more specific, and far more addressable, than that provided by a single risk variant.

Marnie’s three primary complaints were insomnia, intermittent gut issues, and mild cognitive decline. What the report revealed was that these were not three separate problems.

They were connected.

Using IntellxxDNA, Marnie’s clinician gained access to a genomic report uniquely organized for clinical utility, one that transcends a long list of variants and focuses on clinically relevant, high-impact pathways.

Her clinician found something that no standard workup had identified. Marnie was among the 0.5% of the population with two copies of a histamine intolerance variant with a genomic inability to make the enzymes needed for food-related histamine metabolism. This was quietly driving her sleep disruption and gut symptoms. However, this was also affecting her memory in a very different way – with individuals having 2 copies of this variant along with insomnia also being over 20x more likely to report problems with attention and focus which is a different sort of memory problem.

Marnie also lacked the ability to absorb B12 effectively through her gut. B12 is essential for neurological function. And a chronic, undetected deficiency had been quietly undermining her cognitive health for years.

On the cognition side, the report identified a combination of variants that, together, painted a far more complete picture than APOE4 alone:

Notably, Marnie did not carry the BCHE K variant, a common gene variant that is frequently present in cognitive decline cases and interacts with APOE4 to double the risk of cognitive decline compared to those without BCHE K variant. Its absence was itself clinically meaningful.

Marnie, however, did have a mitochondrial membrane variant that affected the cellular energy production that the brain depends on. She also had a combination of IL6 and MTHFR variants influencing inflammation and methylation pathways critical to neurological health. And a gene affecting estrogen production, a variant associated with a doubled risk of Alzheimer’s, and one that had gone entirely unexamined until this report.

This was not a collection of rare mutations. It was the combined effect of common genomic variations interacting across systems with each other, with her nutrient status, and with her biology over decades.

And importantly, the IntellxxDNA genomic report didn’t just reveal these variants. It organized them by relative clinical impact and paired each one with practical, evidence-based intervention considerations such as targeted nutrient support, supplements, lifestyle strategies, and medications where appropriate.

Clinical Case Snapshot

Marnie’s clinician addressed the identified contributors systematically.

• Her gut was supported directly, resolving the histamine and B12 absorption issues that had been undermining her sleep and neurological health.
• Mitochondrial support was introduced.
• Choline was addressed.
• And because of her family history of breast cancer, her estrogen pathway required particular care. Her clinician prescribed raloxifene, a selective estrogen receptor modulator that not only addressed her estrogen-related cognitive risk but carries additional benefits for brain health.

Some of the results were immediate. Her sleep was improved and her gut health was restored with genomically target interventions. Seeing the full benefits as other SNPs were addressed took time. But the most exciting part for Marnie is that the benefits were significant, and they were sustained.

Within 6 months of beginning her genomically targeted protocol Marnie’s memory score was back in the normal range. Some siblings passed away due to poor health, others were in memory care, but Marnie was still living independently with cognition scores remaining in the normal range. Seven years later, at the age of 80, her cognition remains excellent, sitting at 28 out of 30, up from her baseline of 24. Rather than experiencing the natural trajectory of decline Marnie has remained healthy and cognitively intact.

She is active. She lives independently. She is the only one of her five siblings who reached the age of 80 with intact cognition. In fact, many of her 4 siblings, even those younger than her, have passed away.

She is grateful. And her only regret, she says, is that her whole family didn’t do this when she did.

Why This Matters in Structured Practice

Marnie’s case raises a question that every clinician working with cognitive health patients will recognize: when a patient presents with a frightening genetic risk and a family history to match, is the answer simply to monitor or is there something more specific, and more actionable, available?

For Marnie, the answer was clear. But it required looking past the obvious marker.

Most cognitive decline presentations are not driven by one gene. They emerge from subtle genomic variations interacting with the environment, nutrient status, hormonal factors, and each other, across decades of biology that standard workups were never designed to examine.

There is also a practical dimension worth naming directly. Genomic reports represent a meaningful upfront investment, one that clinicians are sometimes hesitant to recommend, and that budget-conscious patients may initially resist.

Marnie, as a retired teacher on a fixed income, felt that hesitation herself. But she also understood, eventually, what the alternative looked like:

Memory care costs upward of $10,000 per month.

A genomic report that identifies actionable contributors early enough to address them is not an expense. It is one of the most cost-effective clinical decisions available, measured not just in dollars, but in years of independent, healthy life.

Without the structured context of a well-designed genomics platform, the drivers behind Marnie’s cognitive trajectory would have remained invisible and unaddressed. With organized genomic insight, prioritization became possible.

And that changed everything about how her care felt and where it went.

Moving from Recognition to Momentum

Genomics does not replace clinical judgment. Genomics supports it.

It gives structure to patterns you’ve already sensed. It helps you see which pathways deserve attention first, next, and why. And it restores forward momentum in cases that might otherwise feel like inevitable decline.

Marnie came in afraid of her seemingly inevitable cognitive future. Seven years later, she is enjoying her life and friendships, driving, and fully functioning in her 80’s, a reality none of her siblings got to experience.

If you’ve sat across from a patient carrying APOE4 and a heavy family history and sensed that a single risk variant wasn’t the whole story, this is the tool that helps you find the rest of it.

Explore how structured genomics moves challenging cases forward with confidence.

Genomic insights should be interpreted within the context of comprehensive clinical evaluation and individualized care.

Improving Mental Health with Genomics: A Smarter, Personalized Approach

If you’ve ever felt like traditional mental health treatments don’t fully work for you, you’re not alone. Mental health isn’t one-size-fits-all—and your genetics play a major role in how your brain responds to stress, neurotransmitters, and even medications.

For too long, treatment for anxiety, depression, and mood disorders has been trial and error. But now, genomics is changing the game, giving us clear, science-backed insights into the root causes of mental health challenges.

Here’s how understanding your DNA can help you improve mental health with precision, not guesswork.

1. Your Genes Influence Brain Chemistry—Know What’s Driving Your Symptoms

Ever wondered why some people handle stress effortlessly while others experience persistent anxiety or depression? Your neurotransmitters—like serotonin, dopamine, and GABA—are influenced by your genetics.

Key genetic factors that impact mental health:

🧬 MTHFR & Folate Metabolism: If you have MTHFR variants, your body struggles to convert folic acid into methylfolate, which is essential for mood regulation & neurotransmitter production.

🧬 COMT & Dopamine Processing: Your COMT gene affects how quickly your body breaks down dopamine—if it’s too fast, you may struggle with motivation & focus; too slow, and you may feel anxious & overstimulated.

🧬 BDNF & Brain Resilience: BDNF (Brain-Derived Neurotrophic Factor) helps with neural repair & mood stability—low levels are linked to depression, anxiety, and cognitive decline.

Why this matters:

Instead of assuming one-size-fits-all solutions work for you, genomics helps pinpoint why your brain functions the way it does, so you can take targeted action.

2. The Right Supplements for YOUR Brain—Not Just Generic Advice

Not everyone responds the same way to supplements for mental health. Your genes determine which nutrients and compounds your brain actually needs.

Example of how genomics guides supplement choices:

💊 Have an MTHFR mutation? You likely need methylfolate instead of standard folic acid to support neurotransmitter balance.

💊 Struggle with high stress & anxiety? If your COMT gene clears dopamine too slowly, adaptogens like rhodiola or phosphatidylserine may be better than stimulants.

💊 BDNF variants impacting mood & resilience? Exercise, omega-3s, and curcumin can help boost brain plasticity & emotional stability.

Instead of throwing random supplements at the problem, genomics removes the guesswork and gives precision recommendations for your unique brain chemistry.

3. Medication Side Effects? Your DNA May Be the Reason

Ever had an extreme reaction to an antidepressant? Or found that SSRIs don’t work for you? Your genetics affect how you metabolize psychiatric medications—which is why some drugs work great for one person but cause side effects in another.

🔬 Your CYP450 genes impact how you process medications—knowing your variants can predict whether you’ll:

✅ Metabolize a medication too fast (making it ineffective)

✅ Process it too slowly (causing side effects & toxicity)

✅ Need a specific type of antidepressant based on your brain chemistry

Bottom line: Instead of trial-and-error prescribing, a genomics-based approach can help your doctor choose the right medication the first time.

4. Lifestyle Adjustments That Actually Work—Based on Your DNA

Not all mental health strategies work the same for everyone. Your DNA can tell you which lifestyle changes are most effective for your brain and mood stability.

🧘 Exercise & Mental Health: If you have BDNF variants, exercise isn’t just helpful—it’s critical for maintaining emotional balance.

☀️ Light Exposure & Circadian Rhythm: Some genes make you more sensitive to blue light, meaning light therapy or early sun exposure can have a bigger impact on mood.

🥑 Nutrition & Mental Health: Your genetics influence how well you absorb key nutrients like omega-3s, magnesium, and choline, which directly affect mood and cognitive function.

By aligning your lifestyle interventions with your DNA, you can get real, lasting improvements in mental health.

5. The Future of Mental Health is Personalized—And It’s Here Now

For years, mental health care has been reactive and generalized—but genomics is revolutionizing treatment, making it personalized, precise, and effective.

✅ Identify genetic drivers of anxiety & depression

✅ Pinpoint the right nutrients, supplements & medications for YOUR brain

✅ Make data-driven lifestyle changes for long-term mental wellness

At IntellxxDNA, we bring clinician-guided genomics to the forefront of mental health care, so you and your provider can make smarter, science-backed decisions for your best brain health.

Ready to take control of your mental health with precision?

Let us match you with an expert clinician who uses genomics to tailor treatment to your unique biology.

A guest post from our clients at Potomac Psychiatry:

I start with the premise that all human disease is genetic.
— Paul Berg, Ph.D., Nobel Laureate

At Potomac Psychiatry we always try to be on the forefront of personalized medicine. By using genomics to help with our clinical decision making, not only are we better able to choose appropriate medications, but we are better able to support our patients naturally with personalized nutrition and supplements, sometimes even allowing us to avoid medications. IntellxxDNA helps us optimize outcomes for everything from anxiety to ADHD to cognitive decline.

Genetic Tests Blueprint Better Mental Health

Why are genetic tests so crucial to blueprinting and building better mental health? As discussed in a prior blog, your DNA creates the information-system blueprint to build out your subatomic, atomic, and molecular mental health in every one of your 30 trillion human cells that influence your mental and physical health. A new genetic test identifies genetic variations that predispose you to “setting your brain on fire” and helps create the roadmap to extinguish that fire to improve mental wellness.

In this blog you will learn about…

• Why rates of mental illness are on the rise
• A new genetic test that creates better mental health through analyzing genetic variations that can be positively affected through the targeted use of gene-specific supplements
• Four genes that affect how your immune system functions, that predispose you to “setting your brain on fire,” and how you can “extinguish them” with specific supplements to improve mental health
• How your immune system and these “brain fire genes” predispose one to developing PTSD, Depression, Bipolar Disorder, and Alzheimer’s Disease
• How to obtain additional information on the role of genetic testing in Root Cause Psychiatry

Our Mental Health Ecosystem

More people than ever are struggling with mental health problems. Why? This is a question that my colleagues and I wrestle with daily. The answers to this question are complex, however there is one that remains quite simple: while the human genome has not materially changed for the last 50,000 years, our environment has altered dramatically, creating a profound effect on which of our genes are expressed, and which are suppressed. How?

As you can see from the mental health ecosystem infographic below, many of the environmental “roots” that affect how our genes are “turned on” or “turned off” have been created, or have dramatically changed, in the last few decades.

For example, over the past several decades we have witnessed increasing levels of environmental toxins, greater challenges getting a full night’s sleep, a Western diet with more processed foods and simple carbohydrates, and now a global pandemic. Amidst all of this turmoil, the exponential rise in the popularity of social media apps like Facebook, which launched less than 20 years ago, has only increased our levels of chronic stress and its effects on our immune system.

Ecosystem Stressors Set Your Brain on Fire

Each of these examples have one important thing in common, they modulate specific genes in your cells to produce increased levels of inflammatory proteins that circulate throughout your body and invade your brain to cause brain inflammation.

It’s not our species’ fault that our “hunter-gatherer world” genome can’t keep up with the fast-paced changes of life in the twenty-first century. However, we do have some control over how we can effectively influence that genome toward better mental health! The good news is that we can determine our personal vulnerabilities to debilitating brain inflammation through a brilliant new genetic test called IntellxxDNA™.

IntellxxDNA Testing Facilitates Root Cause Analysis with Supplement-Based Solutions

IntellxxDNA personalized genomic reports help psychiatrists understand a patient’s individual gene function, which leads to exceptionally powerful, individualized prevention and intervention strategies to blueprint and build better mental health. The best part about IntellxxDNA report is that the gene-targeted interventions include diet, lifestyle, and supplements that have been supported by numerous scientific studies; including their effective doses; leading to a personalized roadmap for optimizing your mental wellness.

IntellxxDNA reports are divided into categories of health conditions showing both risks and benefits of your personal genetic code. As a Clinical Decision Support Tool, a psychiatrist can use an IntellxxDNA Genomic Report to analyze the clinically relevant information about your personal genetic make-up. This includes information about potential interventions that can be used to optimize your mental wellness and brain health.

The connection between our mental health and our biology is irrefutable—and uncovering and focusing on certain “risky” genes can be an essential component of psychiatric treatment. To illustrate this mind-body connection, today I want to explore how certain genetic variations relate to systemic and brain inflammation and poor mental health outcomes, and then discuss how we can use this knowledge to help your immune system help you! In my discussion below on inflammation, I am going to share some of what I have learned as I have studied genomics with IntellxxDNA and combined it with my psychiatric knowledge.

“Brain Fire Genes” Tested by IntellxxDNA

The IL6 Genetic Variant
There are a number of Immune System and Inflammation Genes tested by IntellxxDNA that can tell you quite a bit about your health, and today we will focus on four of them.

A variant of IL6 is known to increase the immune system’s inflammatory response and create cytokines (proteins that cause inflammation) that cross the blood brain barrier into the brain, and activate the glial cells to cause brain inflammation. This IL6 variant also creates a higher risk of mood disorders including depression. Increased release of IL6 in major depressive disorders is associated with a poorer response to treatment and is associated with a wide range of depressive symptoms. Increased IL6 activity may also cause depression through activation of the hypothalamic-pituitary-adrenal (HPA) (“fight, flight or freeze”) axis, or influence neurotransmitter manufacture and breadown; and it also causes the release of other cytokines that cause inflammation, known as TNF Alpha and IL1. Supplements such as sulforaphane, quercetin, and omega 3s can “turn off” this IL6 variant to reduce brain inflammation.

The TNF Alpha Genetic Variant
Numerous studies have shown that patients with mood disorders have increased levels of the TNF Alpha protein coded by this gene. This cytokine also crosses the blood brain barrier, where it activates the microglia that further inflame the brain. A number of other psychiatric conditions are associated with this gene and brain inflammation.

In Autism Spectrum Disorders, levels of TNF Alpha cytokines are 50 times higher than normal in the cerebral spinal fluid of these patients, and there are elevations in IL6 as well. And the higher the levels of TNF Alpha, the more severe the symptoms of autism.

In a study of children with PANDAS/PANS, which affects 1 in 200 children, 100% of them were found to have the genetic variant of TNF Alpha associated with increased brain inflammation. The same TNF Alpha variant confers six times the risk of celiac disease, a condition that is associated with gut inflammation and serious neurological problems, which may be why a gluten-free diet often helps alleviate some of the symptoms of autism.

Luteolin, Quercetin, and Rutin have shown promising results in “treating” this TNF Alpha gene variant in children and adults suffering from autism. Combining all three together decreased TNF Alpha in the bloodstream by 60%, and when given to children with autism, they demonstrated improvements in communication, living skills, and sociability.

This TNF Alpha variant also confers 2.8 times the risk of developing OCD, by activating what is known as the glutamate system in the brain. Glutamate also worsens symptoms of anxiety and mood disorders. Excess glutamate also reduces the brain’s ability to grow new brain cells and create new synaptic connections between them, which can reduce one’s ability to learn new information.

TNF Alpha also makes less serotonin available in the synapse by increasing its reuptake, further contributing to anxiety and depression.

TNF Alpha levels are also much higher in patients suffering from Alzheimer’s Disease, one of the hallmarks of which is an impaired ability to grow new brain cells and make new connections between them. Sulforaphane has been shown to help clear the amyloid protein tangles in the brain cells of these patients—proteins that accumulate to cause cell damage—and reduce brain inflammation. And Lion’s Mane has been shown to reduce mild cognitive impairment by reducing TNF Alpha levels. When the supplement was stopped the improvement went away.

These gene variants can negatively affect health in other ways, such as Crohn’s disease, autoimmune diseases, rheumatoid arthritis, atherosclerosis, type 2 diabetes, and cancer.

This TNF Alpha gene can be “turned off” with supplements such as Lion’s Mane, capsaicin, sulforaphane, and milk thistle, to help bring about symptom relief and better outcomes.

IL6 and TNF Alpha genetic variations can also be involved in promoting “brain fog” which is a common complaint in patients suffering from a chronic mood or anxiety condition, and poor regulation of these genes can also be a precursor to developing dementia.

Now let’s focus on two other genetic variants uncovered by IntellxxDNA testing—IL1A and IL1B—that also promote brain inflammation.

IL1 Alpha and IL1 Beta Genetic Variations
These genes are associated with higher rates of dementia, schizophrenia, and autoimmune diseases, and have been shown to activate those microglial cells we mentioned before. With these two genetic variations, some of the same supplements noted above can also help to switch off their effects, along with Resveratrol, omega 3s, and curcumin.

These four genes not only cause brain inflammation by negatively affecting your immune system, this inflammation in turn accelerates the development of many of the most common mental health problems plaguing us in today’s world.

Bipolar Disorder, PTSD, Depression and Alzheimer’s from “Brain Fire Genes”

Bipolar Disorder: Evidence for involvement of the immune system, and in a broader sense, inflammation in mood disorders, including Depression and Bipolar Disorder, has been steadily accumulating in recent years. In addition, a complex mixture of behavioral changes observed in inflammatory states, which includes mood changes such as anxiety, depression, failure to concentrate, lethargy, and “feeling sick” (my patients describe feeling like they have a low-grade flu) that are associated with proinflammatory cytokines such as TNF Alpha, IL6, and IL1 Beta. These cytokines can actually induce mood disorders in physically ill patients without a previous mental illness; and a great percentage of patients with mood disorders also have autoimmune pathologies, such as hypothyroidism, rheumatoid arthritis, diabetes mellitus, hepatitis, and Crohn’s disease. Patients who suffer from autoimmune diseases also have an increased risk of developing bipolar disorder.

Two studies used PET Scanning to demonstrate a brain inflammation condition in patients with bipolar disorder, including increased activation of immune system cells (glial cells), and damage to brain cells (often reversible with the right supplements, diet, and lifestyle changes) in the hippocampus of bipolar patients compared to healthy controls. The hippocampus is intimately involved in learning new information, and regulating and processing emotions. No wonder these patients complain of brain fog!

PTSD: Elevations in the bloodstream of TNF Alpha, IL6, and IL1 Beta cytokines are also associated with PTSD. And neuroimaging studies in PTSD patients demonstrated that these elevated inflammatory biomarkers are associated with altered structure and functioning in brain regions that are responsible for the regulation of stress and the processing of emotions, including the amygdala, hippocampus, and frontal cortex.

Alzheimer’s Disease: Remember that “methylation gene” – MTHFR? When this genetic variant is combined with one of these inflammation genes, they triple the risk of Alzheimer’s Disease and vascular dementia (caused by a narrowing of the tiny blood vessels in the brain that nourish our neurons with nutrients and oxygen).

Use Genetic Testing to Determine the Root Causes of Brain Inflammation

Knowledge of your personal genome gives you the power to restore your health and improve your relationships by affecting how your genes express themselves. As you have learned in our Root Cause Psychiatry blog series so far, simply identifying symptoms and prescribing medications is not enough.

Without the type of genetic testing provided by IntellxxDNA, a psychiatrist is simply not as effective in treating individuals with chronic unremitting emotional pain—who often present to us feeling horribly broken and hopeless after other treatment efforts failed to improve their symptoms. As you have learned today, chronic inflammation may be one of the most important root causes of all!

To Learn More

If you would like to learn more about Potomac Psychiatry’s Root Cause Psychiatry Program, feel free to contact them.